psaA Antibody

What is PsaA and what is its significance in pneumococcal pathogenesis?

PsaA is a surface-exposed common 37-kilodalton multi-functional lipoprotein detected on all known serotypes of Streptococcus pneumoniae. It functions as part of an ABC-type transport protein complex that transports Mn²⁺ and also serves as an adhesin that plays a major role in pneumococcal attachment to host cells and virulence . The protein is highly conserved across pneumococcal serotypes and has been confirmed in all 90 serotypes of S. pneumoniae through PCR analysis, making it a potential universal marker for this pathogen . Expression of psaA is upregulated during adherence to human lung epithelial cells and in blood or cerebrospinal fluid, highlighting its importance in pneumococcal colonization and invasion processes .

What is the molecular structure of PsaA protein?

The primary translation product of the psaA gene is a 309-amino-acid polypeptide with distinct structural features. It includes a 20-amino acid N-terminal leader sequence containing the prolipoprotein recognition sequence LXXC recognized by signal peptidase II, followed by two (β/α)₄ domains, and an α-helical linker . After signal sequence cleavage, the resulting 290-amino acid mature protein becomes anchored to the bacterial membrane via the N-terminal Cys-linked lipid tail. The protein's structure forms two lobes with a cleft where the metal-binding site is located, which is essential for its function in manganese transport .

What host cellular receptors interact with PsaA?

PsaA has been identified to interact with at least two host cell receptors. E-cadherin expressed on nasopharyngeal epithelial cells has been identified as one receptor for PsaA, making it critical in the initial colonization process . More recent research has identified Annexin A2 (ANXA2) on Detroit 562 nasopharyngeal epithelial cells as another important interaction partner. Experimental evidence shows that lentiviral expression of ANXA2 in HEK 293 T/17 cells, which normally express minimal ANXA2, significantly increased pneumococcal adhesion, while blocking ANXA2 with recombinant PsaA negatively impacted pneumococcal adherence . These interactions highlight the molecular basis of pneumococcal colonization mechanisms.

How is the presence of psaA gene verified across pneumococcal strains?

The presence of the psaA gene across all 90 pneumococcal serotypes has been confirmed using PCR-based methods. When tested with specific primers, 89 of the 90 serotypes produced an 838-bp fragment; only one exception was found in a serotype 16F strain from the American Type Culture Collection (ATCC), which was later determined to be a variant as 20 additional 16F strains from various geographical locations showed successful amplification . The specificity of psaA PCR assays has been verified by the lack of signal from heterologous bacterial species and genera, including viridans group streptococci, demonstrating that this approach can be utilized for specific detection of S. pneumoniae .

How do antibody responses to PsaA develop during infection?

Studies have shown that infants are capable of developing specific antibody responses to PsaA during acute otitis media (AOM) . Children with previous pneumococcal exposure, whether through carriage or AOM, typically show high anti-PsaA antibody concentrations in acute phase sera. The antibody response is strongly associated with low acute phase antibody concentration, suggesting that boosting occurs in individuals with previous exposure . In adults over 50 years with invasive pneumococcal disease (IPD), geometric mean concentrations of antibodies to PsaA increased approximately 25 times higher three weeks after hospital admission compared to admission levels, demonstrating robust immune response to this antigen during invasive infection .

What methodologies are most effective for detecting anti-PsaA antibodies in clinical samples?

Detection of anti-PsaA antibodies in clinical samples is commonly performed using enzyme-linked immunosorbent assay (ELISA). In published research protocols, Immulon 1 plates are coated with recombinant PsaA (typically at 10 μg/ml, 100 μl per well in PBS) and incubated overnight at 4°C . Sera should be tested in duplicate, with antibody binding detected using alkaline phosphatase-conjugated secondary antibodies (such as goat anti-mouse immunoglobulins for mouse studies) followed by substrate development with p-nitrophenyl phosphate . Antibody titers are determined as the highest dilution of serum giving a detectable absorbance reading above background.

For clinical applications, it's important to establish appropriate controls and background levels. In research settings, background values are often defined using sera from subjects immunized with unrelated proteins (e.g., mouse serum albumin in animal studies) diluted 1:100 in PBS . Titers below detection are typically assigned values ≤100 for statistical purposes.

How does the surface accessibility of PsaA affect its potential as a vaccine target?

Surface accessibility is a critical factor determining the effectiveness of antibodies against bacterial surface proteins. Flow cytometry studies have demonstrated that PsaA is not readily detectable on the surface of intact pneumococcal strains, in contrast to other surface proteins like PspA which shows high accessibility . This limited surface accessibility appears to impact protection efficacy, as mice with passively or actively acquired antibodies to PsaA were not effectively protected against systemic pneumococcal infection, whereas mice with antibodies to more accessible targets like PspA or capsular polysaccharides showed significant protection .

These findings suggest that despite PsaA being highly conserved and immunogenic, its limited accessibility to circulating antibodies may reduce its effectiveness as a standalone vaccine target. This represents an important consideration for vaccine development strategies targeting this protein.

What experimental approaches can be used to evaluate PsaA-host receptor interactions?

Several complementary approaches can be used to study PsaA-host receptor interactions:

• Binding assays with recombinant proteins: Using purified recombinant PsaA and potential host receptors like E-cadherin or Annexin A2 in ELISA or surface plasmon resonance experiments to determine binding affinities and kinetics.

• Cell-based assays: Experiments demonstrating that lentiviral expression of receptors (e.g., ANXA2) in receptor-negative cell lines significantly increases pneumococcal adhesion .

• Blocking experiments: Blocking potential receptors with recombinant PsaA and measuring the impact on pneumococcal adherence to host cells. Studies have shown that blocking ANXA2 with recombinant PsaA negatively impacts pneumococcal adherence to ANXA2-transduced HEK cells .

• Genetic approaches: Creating receptor knockout cell lines or using RNA interference to suppress receptor expression and evaluating the effect on bacterial adherence.

• Microscopy techniques: Immunofluorescence or confocal microscopy to visualize colocalization of PsaA with its receptors during bacterial attachment to host cells.

What are the technical considerations for producing and characterizing monoclonal antibodies against PsaA?

When producing monoclonal antibodies against PsaA, several technical considerations are important:

Antigen preparation:

• Use purified PsaA protein, typically from S. pneumoniae serotype 22F, which has been shown to be effective for antibody generation .

• Ensure proper protein folding to maintain conformational epitopes.

Immunization protocol:

• Mouse immunization is commonly used, with multiple injections of purified PsaA typically emulsified in adjuvant .

• Intraperitoneal immunization routes have been successful for generating high-titer antibodies.

Antibody characterization:

• Isotype determination is important - successful anti-PsaA antibodies have included both IgG1 and IgG2b subclasses .

• Western blotting should be conducted to verify specificity.

• Immunodot assays can be used to test cross-reactivity across pneumococcal serotypes .

Applications testing:

• Validate antibodies for specific applications like Western blotting or other immunoassays .

• Test reactivity against multiple pneumococcal serotypes to confirm broad recognition.

How can PsaA antibodies be utilized in pneumococcal diagnostic assays?

PsaA antibodies offer significant potential for developing pneumococcal diagnostic assays due to PsaA being conserved across all 90 pneumococcal serotypes. Several diagnostic applications include:

• PCR-based detection: The psaA gene can be detected by PCR, with primers designed to amplify an 838-bp fragment. This approach has demonstrated potential for clinical application by successfully detecting pneumococci in culture-positive nasopharyngeal specimens .

• Immunoassays: Monoclonal antibodies against PsaA can be used in various immunoassay formats including ELISA, lateral flow tests, or multiplex assays to detect pneumococcal proteins directly from clinical samples.

• Serological testing: Measuring anti-PsaA antibody levels in patient sera can provide evidence of recent pneumococcal infection or colonization. This is particularly valuable since all patients with invasive pneumococcal disease show significant antibody responses to PsaA, with levels increasing approximately 25-fold during convalescence .

• Differential diagnosis: Since PsaA antibody levels remain stable in patients with invasive diseases caused by other microorganisms, comparing acute and convalescent antibody levels can help differentiate pneumococcal from non-pneumococcal infections .

What factors influence the immunogenicity of PsaA in different population groups?

Several factors affect the immunogenicity of PsaA across different populations:

• Age: Children show variable antibody responses to PsaA, with the capacity to develop specific antibodies during acute otitis media . Adults over 50 years demonstrate robust responses during invasive disease .

• Previous exposure: Children with previous pneumococcal contacts (either carriage or infection) typically have higher baseline anti-PsaA concentrations regardless of the nature of current pneumococcal contact . This suggests that repeated exposure enhances immunological memory.

• Current infection status: Among children without previous pneumococcal exposure, those with pneumococcal AOM have lower antibody concentrations than those with pneumococcal carriage only .

• Baseline antibody levels: The antibody response to PsaA is strongly associated with low acute phase antibody concentration, indicating that individuals with lower baseline levels show more pronounced responses .

• Immunization route: In mouse studies, intranasal immunization routes elicited higher antibody titers than oral immunization, demonstrating the importance of delivery method in determining immune response magnitude .

What methodological considerations are important when evaluating PsaA as a vaccine immunogen?

When evaluating PsaA as a vaccine immunogen, researchers should consider:

• Protein formulation: The selection of appropriate adjuvants and delivery systems is crucial. Common approaches include emulsification in incomplete Freund's adjuvant for animal studies .

• Accessibility assessment: Since PsaA shows limited surface accessibility on intact bacteria, strategies to enhance accessibility or combination with more exposed antigens should be considered .

• Challenge models: Appropriate animal challenge models that reflect different aspects of pneumococcal disease (colonization vs. invasive disease) should be employed to comprehensively assess protection.

• Combination strategies: Given the limited protective efficacy of PsaA antibodies alone against systemic challenge, combination with other pneumococcal proteins (like PspA) or use as a carrier protein for capsular polysaccharides might enhance protection .

• Cross-serotype protection: Although PsaA is conserved across serotypes, verification of cross-protection against multiple clinical isolates is essential.

• Correlates of protection: Establishing correlations between antibody titers, functional activity of antibodies, and protection levels is critical for predicting vaccine efficacy.